The present study implies that preserving functional adiponectin sensitivity in patients suffering from metabolic diseases (e.g., diabetes, obesity, metabolic syndrome) might be also beneficial for preventing bone fragility. This evidence concerns the gene ADIPOQ and metabolic disease.